3′-End Small RNA Modification for Nuclease-Resistant Therapeutics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Small RNAs are unstable in biological environments due to quick degradation by nucleases, limiting their therapeutic effects.
Innovation Solution
Modifying the 3′ end of small RNA molecules with non-templated nucleotides, such as cytidines or uridines, to enhance stability and prolong in vivo half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small RNA molecules are used for therapeutic purposes, then they provide specificity and functional diversity, but they are quickly degraded by nucleases resulting in short in vivo half-life
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of small RNA molecules through phosphorylation at the 5' end and adding non-templated nucleotides at the 3' end. These structural parameter changes protect the small RNAs from nuclease degradation while maintaining their ability to bind to target mRNAs and induce gene silencing, thereby extending their in vivo half-life without compromising therapeutic effectiveness
Solution Approach 2:
The patent creates composite structures by combining modified small RNA sequences with specific chemical modifications including 5' phosphorylation groups and 3' non-templated nucleotide additions. These composite modifications form a protective framework that enhances stability against nucleases while preserving the functional core of the small RNA molecule for therapeutic action
2Stability of the object's composition
If the 3′ end of small RNA molecules is modified with non-templated nucleotides, then stability is improved, but the structure becomes more complex
Solution Approach 1:
The patent applies local quality by making specific modifications only at the terminal regions of the small RNA molecule (5' phosphorylation and 3' non-templated nucleotide addition) rather than throughout the entire sequence. This localized approach enhances stability without significantly complicating the overall molecular structure or interfering with the central functional region that binds to target mRNA
Solution Approach 2:
The patent implements preliminary action by pre-modifying the 3' end of small RNA molecules with non-templated nucleotides before administration. This advance modification creates a protective structure that preemptively prevents nuclease degradation, establishing enhanced stability before the molecule encounters biological challenges in vivo
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Improved stability and prolonged half-life of small RNAs without affecting their therapeutic effects, demonstrated by decreased degradation in cells.
Implementation Method 1
contacting the small RNA molecule with an exonuclease to remove the 3′ overhang of the small RNA molecule
Implementation Method 2
adding one or more non-templated nucleotides to the 3′ end of the small RNA molecule
Data Source
AI summary
Provided are methods for improving stability of small therapeutic RNAs by adding one or more non-templated nucleotides such as cytidines and uridines to the 3′ end of the small therapeutic RNAs. Also disclosed are modified small therapeutic RNAs comprising one or more non-templated nucleotides such as cytidines and uridines at the 3′ end and pharmaceutical compositions comprising such modified small therapeutic RNAs.